Prophase Labs Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Prophase Labs Inc 's ROA in the second quarter of 2026?
Prophase Labs Inc recorded a cumulative net loss of $-23 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -21.68%.

However, within the Healthcare sector 555 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4214, from total ROA ranking in the first quarter of 2026 at 4247.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	173.11 %	134.4 %	85.93 %	-25.59 %	-53.29 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-23	-24	-15	-42	-41
Return On Assets (TTM)	-21.68 %	-27.9 %	-21.24 %	-75.06 %	-67.72 %
PRPH's Total Ranking	# 4214	# 4247	# 4248	# 4242	# 4955
Total Assets (TTM) in million	115	117	120	66	42
Seq. Total Assets Change	-2.25 %	-1.91 %	82.25 %	56.28 %	-16.1 %
Seq. Net Income Change	-	-	-	-	-

PRPH's 5 Years Annual ROA >> Back to PRPH Management Effectiveness >> Compare PRPH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 231
Sector	# 556
Overall	# 4367

Return On Assets Statistics
High	Average	Low
178.95 %	-6.97 %	-75.46 %
(Mar 31 2017)		(Sep 30 2025)

Financial Statements
Prophase Labs Inc 's Assets	$ 115 million	PRPH's Balance sheet
Prophase Labs Inc 's Income	$ -3 million	Quarterly PRPH's Income Statement
PRPH's Income by Division		See PRPH's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	68.69 %	-31.14 %	4.16 %	-3.24 %	218.9 %
Total Assets in million	103	61	89	85	88
Y / Y Net Income Change	-	-	-	194.32 %	-
Net Income in million	-15	-53	-17	18	6
Annual Return On Assets	-14.26 %	-87.09 %	-18.86 %	21.61 %	7.11 %

PRPH's 5 Years Annual ROA >> Back to PRPH Management Effectiveness >> Compare PRPH ROA to its Competitors

More Return On Assets Ratios
PRPH's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PRPH's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PRPH's Competitors
Subscribers only: Roa for Prophase Labs Inc 's Suppliers
Subscribers only: Return On Assets for PRPH's Customers

You may also want to know
PRPH's Roi	PRPH's Inventory Turnover Ratio	PRPH's Growth Rates	PRPH's Dividend Comparisons
	PRPH's Profitability Ratios	PRPH's Asset Turnover Ratio	PRPH's Dividend Growth
PRPH's Roe	PRPH's Valuation Ratios	PRPH's Financial Strength Ratios	PRPH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-31T13:29:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.